Related Experiment Video
Updated: May 7, 2026
Intravitreous Injection for Establishing Ocular Diseases Model
Published on: October 1, 2007
ISO-1, a macrophage migration inhibitory factor antagonist, prevents N-methyl-D-aspartate-induced retinal damage
Taeko Naruoka1, Tsutomu Nakahara, Yo Tsuda
1Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.
Abstract:
Macrophage migration inhibitory factor (MIF) has been shown to play an important role in a variety of inflammatory and immune-mediated diseases. The inflammatory responses contribute to retinal neuronal degeneration. However, the role of MIF in the progression of retinal degeneration has not yet been elucidated. In this study, we determined whether pharmacological inhibition of MIF protects against the retinal damage induced by N-methyl-D-aspartate (NMDA) in rats. Intravitreal injection of NMDA (200 nmol) resulted in (1) cell loss in the ganglion cell layer and reduction in the thickness of the inner plexiform layer, (2) an increase in apoptotic cells, (3) a decrease in parvalbumin-positive amacrine cells, (4) accumulation of leukocytes, and (5) microglia activation. Injection of (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1, 100 nmol), a MIF antagonist, significantly attenuated these NMDA-induced responses. These findings suggest that ISO-1 exerts protective effects against retinal injuries and that MIF may be a target for neuroprotective intervention in retinal diseases associated with glutamate-induced excitotoxicity.
Insights
Macrophage migration inhibitory factor (MIF) inhibition protects against retinal damage. Blocking MIF with ISO-1 reduced NMDA-induced neurodegeneration, suggesting MIF as a therapeutic target for retinal diseases.
Area of Science:
- Neuroscience
- Immunology
- Ophthalmology
Background:
- Macrophage migration inhibitory factor (MIF) is implicated in inflammatory and immune diseases.
- Inflammation contributes to retinal neuronal degeneration, but MIF's role is unclear.
- Glutamate excitotoxicity, mediated by N-methyl-D-aspartate (NMDA), is a key factor in retinal damage.
Purpose of the Study:
- To investigate the role of MIF in NMDA-induced retinal degeneration.
- To determine if pharmacological inhibition of MIF offers neuroprotection against retinal damage.
Main Methods:
- Rats received intravitreal injections of NMDA (200 nmol) to induce retinal damage.
- NMDA-induced damage included cell loss, apoptosis, amacrine cell reduction, leukocyte accumulation, and microglia activation.
- Rats were treated with (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1, 100 nmol), a MIF antagonist.
Main Results:
- NMDA injection caused significant retinal damage, including ganglion cell layer loss and inner plexiform layer thinning.
- NMDA increased apoptotic cells and decreased parvalbumin-positive amacrine cells.
- ISO-1 treatment significantly attenuated all observed NMDA-induced retinal injury markers.
- ISO-1 reduced leukocyte accumulation and microglia activation in the retina.
Conclusions:
- Pharmacological inhibition of MIF with ISO-1 demonstrates neuroprotective effects against NMDA-induced retinal injury.
- MIF plays a critical role in the inflammatory and degenerative processes following retinal excitotoxicity.
- MIF inhibition represents a potential therapeutic strategy for neuroprotection in retinal diseases involving glutamate excitotoxicity.
